NDAORALTABLET
Approved
Oct 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
3/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOTRIENT (pazopanib hydrochloride) is an oral small-molecule tyrosine kinase inhibitor approved in 2009 for renal cell carcinoma and soft tissue sarcoma. It inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and growth, reducing blood supply to tumors and slowing cancer progression.
$0.098BPart D
LOE ApproachingProduct approaching loss of exclusivity with moderate Part D spending (~$98M in 2023), suggesting a contracting team focused on patient retention and managed care.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Started Feb 2018
5 enrolled
Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8+2 more
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Started Mar 2015
178 enrolled
Adult LiposarcomaMetastatic LiposarcomaMetastatic Osteosarcoma+4 more
Evaluation of Votrient in Angiosarcoma
Started Jul 2014
26 enrolled
Angiosarcoma
Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma
Started Apr 2013
21 enrolled
Sarcoma, Soft-tissue
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Started Nov 2012
51 enrolled
Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer
Worked on VOTRIENT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.